Oncodesign Precision Medicine S.A.
EEURONEXT:ALOPM0.30
EUR
-0.03
(-8.26%)
ISIN
FR001400CM63
Return %
Stock
S&P 500
1Y
-26.29
14.39
3Y
-85.65
81.42
5Y
- -
68.62
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Philippe Genne
- Full Time Employees
- 13
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dijon France
- IPO Date
- Oct 5, 2022
- Website
- oncodesign.com
- Similar Companies
- Business
- Oncodesign Precision Medicine S.A. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of targeted therapies and precision medicine solutions for resistant and metastatic cancers, autoimmune conditions, and neurodegenerative disorders. Founded in 1995 and headquartered in Dijon, France, the company operates as an independent publicly traded entity following its demerger and spin-off from the historical Oncodesign group in 2022. The company conducts research and clinical development across primary technological platforms: Nanocyclix, a proprietary medicinal chemistry engine featuring a chemical library of approximately 12,000 macrocyclic kinase inhibitors engineered to design selective, potent, and brain-penetrant small molecules against intractable and novel kinase targets; OncoSNIPER, an artificial intelligence and bioinformatics platform leveraging multi-omics patient data and algorithmic modeling to validate therapeutic targets; and PROMETHE, a radiotheranostics platform focused on the identification, radiolabeling, and systemic delivery of targeted radiotherapy agents and companion diagnostics for gastrointestinal, pancreatic, and refractory solid tumors. The company's therapeutic and diagnostic product portfolio comprises: OPM-101, an orally bioavailable, highly selective receptor-interacting protein kinase 2 (RIPK2) inhibitor developed for immuno-oncology indications and chronic gastrointestinal inflammatory diseases; OPM-201, a potent, brain-penetrant leucine-rich repeat kinase 2 (LRRK2) inhibitor designed for the treatment of Parkinson's disease; OPM-102, a proprietary preclinical small-molecule kinase inhibitor program for targeted oncology; and a suite of systemic radiotheranostic assets utilizing radiolabeled peptides and antibodies for targeted radionuclide therapy and precision molecular imaging. The company also engages in strategic co-development, licensing, and translational research agreements with academic institutions, biotechnology firms, and multinational pharmaceutical enterprises across Europe and international markets. In recent developments, Oncodesign Precision Medicine S.A. has implemented significant strategic realignments and advanced its clinical-stage pipeline. In late 2024, the company regained full global development and commercial rights to its lead Parkinson's disease asset, OPM-201, following the completion of Phase I clinical studies previously conducted in partnership with Servier. In 2025, the company advanced OPM-101 into clinical trial execution by submitting the regulatory protocol and securing clearance for the Phase 1b/2a REVERT immuno-oncology study. To optimize resource allocation toward its priority clinical assets, the company streamlined its external alliances by concluding its early-stage research collaboration with Navigo Proteins in late 2025. To fund ongoing clinical development and extend operational liquidity, the company secured an equity financing line of up to 5 million euros with IRIS in April 2025. In early 2026, the company was awarded strategic grant funding from The Michael J. Fox Foundation for Parkinson's Research to accelerate the clinical and translational advancement of OPM-201.